X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3940) 3940
Book Review (1507) 1507
Publication (323) 323
Book Chapter (24) 24
Conference Proceeding (12) 12
Magazine Article (4) 4
Presentation (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (3363) 3363
humans (2839) 2839
glucagon-like peptide-1 (2080) 2080
diabetes mellitus, type 2 - drug therapy (1524) 1524
male (1478) 1478
endocrinology & metabolism (1376) 1376
type 2 diabetes (1337) 1337
diabetes (1255) 1255
animals (1207) 1207
female (1133) 1133
hypoglycemic agents - therapeutic use (1128) 1128
glucose (950) 950
glucagon (879) 879
middle aged (851) 851
insulin (844) 844
pharmacology & pharmacy (738) 738
liraglutide (732) 732
glycemic control (656) 656
adult (644) 644
peptides (644) 644
hypoglycemic agents - adverse effects (638) 638
obesity (623) 623
treatment outcome (579) 579
glucagon-like peptide 1 (571) 571
blood glucose - metabolism (570) 570
glp-1 (557) 557
glucagon-like peptide 1 - analogs & derivatives (548) 548
aged (537) 537
diabetes mellitus (537) 537
exenatide (526) 526
hypoglycemic agents - administration & dosage (509) 509
diabetes mellitus, type 2 - blood (494) 494
glucagon-like peptide 1 - therapeutic use (467) 467
care and treatment (462) 462
double-blind (455) 455
dextrose (454) 454
analysis (446) 446
blood glucose - drug effects (439) 439
drug therapy (424) 424
hypoglycemic agents (421) 421
metformin (421) 421
research (411) 411
internal medicine (407) 407
dipeptidyl-peptidase iv inhibitors - therapeutic use (405) 405
mice (394) 394
hypoglycemic agents - pharmacology (390) 390
risk factors (387) 387
diabetes therapy (379) 379
abridged index medicus (377) 377
beta-cell function (368) 368
glucagon-like peptide-1 receptor (367) 367
rats (365) 365
clinical trials (364) 364
medicine & public health (364) 364
type-2 diabetes-mellitus (362) 362
insulin resistance (358) 358
peptides - therapeutic use (356) 356
glucagon-like peptide 1 - metabolism (353) 353
health aspects (352) 352
diabetes mellitus, type 2 - metabolism (336) 336
physiological aspects (333) 333
double-blind method (327) 327
safety (323) 323
hyperglycemia (317) 317
body weight (315) 315
insulin - blood (311) 311
drug therapy, combination (304) 304
insulin - metabolism (292) 292
glucagon-like peptide-1 receptor - agonists (277) 277
medicine, general & internal (277) 277
venoms - therapeutic use (272) 272
receptors, glucagon - agonists (270) 270
secretion (269) 269
rodents (267) 267
glucagon-like peptide 1 - blood (266) 266
open-label (265) 265
type 2 diabetes mellitus (263) 263
metabolism (261) 261
glucagon-like peptide 1 - adverse effects (257) 257
hypoglycemia (255) 255
review (255) 255
diabetes mellitus, type 2 - complications (252) 252
efficacy (252) 252
glycated hemoglobin a - metabolism (250) 250
glucose metabolism (246) 246
incretins - therapeutic use (240) 240
sitagliptin (235) 235
glucagon-like peptide 1 - administration & dosage (230) 230
dipeptidyl peptidase-4 inhibitor (224) 224
food-intake (224) 224
nutrition & dietetics (219) 219
obesity - drug therapy (218) 218
digestive, oral, and skin physiology (217) 217
insulin secretion (215) 215
incretin (212) 212
drug administration schedule (209) 209
peptides - administration & dosage (209) 209
diabetes mellitus, type 2 - physiopathology (206) 206
glucagon-like peptide 1 - agonists (206) 206
insulin-secretion (206) 206
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3869) 3869
German (27) 27
Spanish (17) 17
Japanese (10) 10
French (7) 7
Danish (4) 4
Korean (4) 4
Portuguese (3) 3
Russian (3) 3
Chinese (2) 2
Czech (2) 2
Hungarian (2) 2
Italian (2) 2
Dutch (1) 1
Norwegian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9683, pp. 39 - 47
Summary Background Unlike most antihyperglycaemic drugs, glucagon-like peptide-1 (GLP-1) receptor agonists have a glucose-dependent action and promote weight... 
Internal Medicine | NON-INFERIORITY | METFORMIN | MEDICINE, GENERAL & INTERNAL | GLYCEMIC CONTROL | SULFONYLUREA | GLUCAGON-LIKE PEPTIDE-1 | HUMAN GLP-1 ANALOG | BETA-CELL MASS | TREATED PATIENTS | ACUTE-PANCREATITIS | INSULIN GLARGINE | Nausea - chemically induced | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Male | Diabetes Mellitus, Type 2 - metabolism | Weight Loss - drug effects | Dose-Response Relationship, Drug | Glucagon-Like Peptide 1 - agonists | Injections, Subcutaneous | Female | Hypoglycemia - chemically induced | Hypoglycemic Agents - therapeutic use | Drug Administration Schedule | Peptides - chemistry | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Glucagon-Like Peptide 1 - chemistry | Linear Models | Logistic Models | Treatment Outcome | Hypoglycemic Agents - chemistry | Blood Glucose - drug effects | Analysis of Variance | Venoms - therapeutic use | Venoms - chemistry | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Liraglutide | Peptides - adverse effects | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Hypoglycemic agents | Dosage and administration | Drug therapy | Molecular structure | Clinical trials | Diabetes | Clinical medicine | Apoptosis | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9951, pp. 1349 - 1357
Summary Background Dulaglutide and liraglutide, both glucagon-like peptide-1 (GLP-1) receptor agonists, improve glycaemic control and reduce weight in patients... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | GLYCEMIC CONTROL | EFFICACY | PHYSICAL-ACTIVITIES | SAFETY | PARALLEL-GROUP | EXENATIDE | ANALOG LIRAGLUTIDE | GATEKEEPING PROCEDURES | DAILY LIVING QUESTIONNAIRE | PEPTIDE-1 RECEPTOR AGONISTS | Metformin - therapeutic use | Glucagon-Like Peptide 1 - administration & dosage | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Immunoglobulin Fc Fragments - administration & dosage | Hypoglycemic Agents - administration & dosage | Fasting - blood | Female | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Treatment Outcome | Glucagon-Like Peptides - adverse effects | Diabetes Mellitus, Type 2 - blood | Analysis of Variance | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Liraglutide | Type 2 diabetes | Usage | Research | Comparative analysis | Drug therapy | Clinical trials | Enzymes | Blood pressure | Diabetes | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2015, Volume 373, Issue 1, pp. 11 - 22
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 07/2013, Volume 15, Issue 7, pp. 642 - 649
Aim Assess the pharmacodynamics of lixisenatide once daily (QD) versus liraglutide QD in type 2 diabetes insufficiently controlled on metformin. Methods In... 
metformin | GLP | receptor | type 2 diabetes | pharmacodynamics | Type 2 diabetes | Pharmacodynamics | GLP-1 | Metformin | Receptor | FASTING PLASMA-GLUCOSE | GLYCEMIC CONTROL | SAFETY | EXENATIDE | OPEN-LABEL | PEPTIDE-1 ANALOG | ENDOCRINOLOGY & METABOLISM | POSTPRANDIAL HYPERGLYCEMIA | DOUBLE-BLIND | GLP-1 RECEPTOR AGONIST | PLACEBO-CONTROLLED TRIAL | Glycated Hemoglobin A - analysis | Metformin - therapeutic use | C-Peptide - blood | Glucagon-Like Peptide 1 - administration & dosage | Humans | Middle Aged | Male | Glucagon - blood | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Injections, Subcutaneous | Adult | Female | Drug Resistance | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Drug Administration Schedule | Hyperinsulinism - prevention & control | Glucagon-Like Peptide 1 - analogs & derivatives | Diabetes Mellitus, Type 2 - blood | Incretins - adverse effects | Aged | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Incretins - administration & dosage | Liraglutide | Peptides - adverse effects | Peptides - therapeutic use | Glucagon-Like Peptide 1 - therapeutic use | Care and treatment | Glucagon | Hypoglycemic agents | Glucose | Dextrose | Diabetes therapy | Index Medicus | Original
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2009, Volume 373, Issue 9662, pp. 473 - 481
Journal Article